Gufic Biosciences Limited (Gufic) have received approval from National Medical Products Administration (NMPA), China for our product PRILOCAINE (API) which is an amide-type local anaesthetic of fast onset and intermediate duration of action. This approval shall help commercialization of the said product in China and explore Chinese market.

Prilocaine has a clinical profile similar to lidocaine and is used for infiltration, peripheral nerve blocks and spinal and epidural anaesthesia. Also, in combination with lidocaine, it is used for surface anaesthesia.

Prilocaine offers a significantly greater duration and safety margin without a vasopressor. Hence, addition of epinephrine is not necessary to prolong the duration of action, which can be an advantage when epinephrine is contraindicated.

Prilocaine shows the least systemic toxicity of all amide local anaesthetics and is therefore useful for intravenous regional anaesthesia.

Prilocaine has the highest clearance of all amino-amide local anaesthetics, more than twice the clearance of lidocaine. Together with its larger distribution volume, this feature is responsible for the considerably lower prilocaine plasma concentration compared to lidocaine and mepivacaine after regional anaesthesia. As a consequence, prilocaine reaches toxic blood concentrations very rarely.

Prilocaine is associated with far fewer reported cases of transient neurological symptoms than lidocaine or me

pivacaine.